747 A phase 1 trial of IO-202, an antagonist antibody targeting myeloid checkpoint LILRB4 (ILT3), as monotherapy and in combination with pembrolizumab in adult patients with advanced relapsed or refractory solid tumors

Authors :: Aung Naing
John Powderly
Meredith Pelster
Alexander Spira
Reva Schneider
Paul Woodard
Luke Chung
Elizabeth Wieland
Sydney Ray
Kyu Hong
Tao Huang
X Charlene Liao
Hong Xiang
Heinz-Josef Lenz
Wen Hong Lin
Source :: Regular and Young Investigator Award Abstracts.
Publication Year :: 2022
Publisher :: BMJ Publishing Group Ltd, 2022.

Tools